NEW YORK (GenomeWeb News) – Cellectis and Genoway today announced a sublicensing deal covering Cellectis' homologous recombination technology.

The deal makes animal model firm Genoway the exclusive provider of the technology for research applications in genetically modified rodents. Cellectis retains rights to it for all other applications, such as bioproduction and therapeutics. Cellectis licenses the technology from Institut Pasteur.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.